Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1977 1
1982 2
1983 1
1987 1
1992 1
1996 1
1998 4
2001 1
2005 2
2010 3
2011 2
2012 3
2013 2
2014 1
2015 1
2017 1
2018 1
2019 1
2022 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Socinski MA, et al. Among authors: iglesias jl. J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547591 Clinical Trial.
OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
Lago V, Segarra-Vidal B, Cappucio S, Angeles MA, Fotopoulou C, Muallem MZ, Manzanedo I, Iglesias JLS, Chacón E, Padilla-Iserte P, Fagotti A, Ferron G, Kluge L, Vargiu V, Del M, Scambia G, Minig L, Tejerizo Á, Segovia MG, Cascales-Campos PA; OVA-LEAK Collaborative Group; Hervás D, Domingo S. Lago V, et al. Among authors: iglesias jls. Gynecol Oncol. 2022 Oct;167(1):22-27. doi: 10.1016/j.ygyno.2022.08.004. Epub 2022 Sep 2. Gynecol Oncol. 2022. PMID: 36058743
Nursing Students' Perceptions on Healthcare-Associated Infection Control and Prevention Teaching and Learning Experience in Portugal.
Parreira P, Santos-Costa P, Pardal J, Neves T, Bernardes RA, Serambeque B, Sousa LB, Graveto J, Silén-Lipponen M, Korhonen U, Koponen L, Myllymäki M, Yurrebaso Macho A, Mayens ALW, Picado Valverde EM, Guzmán Ordaz R, Juanes Méndez JA, Iglesias JLP, Canelo JAM, Jankowiak-Bernaciak A, Patrzała A, Bączyk G, Basa A, do Sacramento Costa Reis AM, Simões JA, Torres AL, do Rosário Pinto M, Salgueiro-Oliveira A. Parreira P, et al. Among authors: iglesias jlp. J Pers Med. 2022 Jan 28;12(2):180. doi: 10.3390/jpm12020180. J Pers Med. 2022. PMID: 35207668 Free PMC article.
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D; For ANZGOG and HCRN Collaborative Groups. Lindemann K, et al. Among authors: iglesias jl. Cancer Chemother Pharmacol. 2019 Jan;83(1):97-105. doi: 10.1007/s00280-018-3706-5. Epub 2018 Oct 27. Cancer Chemother Pharmacol. 2019. PMID: 30368585 Clinical Trial.
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.
Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Fernández C, Iglesias JL, Corral G, Pérez-Ramos L, Montilla L, Zeaiter A, Lubomirov R. Moreno I, et al. Among authors: iglesias jl. Pharmaceuticals (Basel). 2024 Jan 30;17(2):182. doi: 10.3390/ph17020182. Pharmaceuticals (Basel). 2024. PMID: 38399397 Free PMC article.
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Jimeno A, et al. Among authors: iglesias jl. Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20. Invest New Drugs. 2017. PMID: 28105566 Clinical Trial.
32 results